77 results about "Retinol binding protein" patented technology

Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and / or prevention of age-related macular degeneration and / or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.

The invention relates to a double antibody latex enhanced retinol binding protein detection kit. More specifically, the invention discloses a double antibody coating latex enhanced immunoturbidimetry kit for detecting retinol binding protein. The kit contains a reagent 1, a reagent 2 and a calibrator. Paring monoclonal antibody A and B are respectively coated on latex particles. Coated antibody is bonded with RBP to be detected, and a plurality of bonders are aggregated together to form detectable turbidity change. The detection kit provided by the invention has high sensitivity, can be used to detect urine samples and serum samples and can be used as nutritive index to detect RBP in serum. Simultaneously, through the detection of RBP in urine, the kit is sensitive to the damage degree of renal proximal tubule.

The invention provides a kit for simultaneously detecting RBP in a urine sample and a serum sample. The kit comprises a reagent R1 and a reagent R2, the reagent R1 is a polymer buffer solution having an agglomeration promotion effect, the reagent R2 is a buffer solution containing a latex-antibody crosslink, and the latex-antibody crosslink comprises anti-RBP polyclonal antibody marked large latex particles and anti-RBP monoclonal antibody marked small latex particles. The kit which adopts a composite monoclonal and polyclonal antibody sensitized latex enhanced immune detection method has the advantages of simultaneous satisfying of the requirements comprising good specificity, high sensitivity and wide linear range, small antibody application amount, and cost reduction, and can be simultaneously used for the clinic detection of the RBP in human blood and urine.

The invention relates to the technical field of biotechnology, and particularly discloses a kit for detecting retinol binding protein content by using latex immunoturbidimetry. The kit comprises a reagent R1, a reagent R2 and a standard product, wherein the reagent R1 is buffer solution with pH (Potential of Hydrogen) value of 6-9; the reagent R2 is latex reagent coated by anti-retinol binding protein double antibodies; and the standard product is retinol binding protein solution with pH value of 5-8. According to the kit, the retinol binding protein content in a sample can be detected by using the latex immunoturbidimetry; the sensitivity is high and can reach 0.042 mg / L; and the kit has the advantages of high stability, easiness and quickness in operation, high specificity, low probability of interference, accurate quantification and broad application prospect.

A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and / or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and / or serotransferrin protein.

A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and / or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and / or serotransferrin protein;

The invention relates to the field of medical immonological in vitro diagnosis and in particular relates to a retinol binding protein assay kit based on latex particle coating. The assay kit comprises a reagent R1, a reagent R2 and a calibrator, wherein the reagent R1 is a Tris-HCl buffer system, and comprises a Tris-HCl buffer solution, a polymer and ethylene diamine tetraacetic acid; the reagent R2 comprises goat anti human retinol binding protein polyclonal antibody coated polystyrene latex particle sensitized granules and a phosphate buffer solution; and the reference calibrator comprises bovine serum matrix, as well as 0.2-2.2% of antiseptic and 1-10% of stabilizer according to the volume percentage of the bovine serum matrix. Compared with the prior art, the assay kit can be used for assistant diagnosis of kidney diseases and assistant diagnosis of mal-nutrition, and has high clinical application value.

A retinol-binding protein assay kit in the market at present has good specificity and insufficient sensitivity or has high sensitivity and poor specificity because the purity of antibodies is insufficient or the potency cannot meet the requirement. The invention provides a double antibody complex retinol-binding protein assay kit, which consists of three parts, namely, a reagent R1, a reagent R2 and calibration materials. The reagent R1 is a phosphate buffer system which consists of phosphate buffer solution with the pH of 7.2 to 7.6, polyethylene glycol 6000-8000 and ethylene diamine tetraacetic acid; the reagent R2 is antibody solution which consists of mouse anti-human monoclonal antibody, rabbit anti-human polyclonal antibody, phosphate buffer solution with the pH of 7.2 to 7.6 and the ethylene diamine tetraacetic acid. By adopting a complex antibody of the polyclonal antibody and monoclonal antibody, the sensitivity and high linearity are guaranteed, and the accuracy of the measured result is greatly improved.

Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and / or prevention of age-related macular degeneration and / or dystrophies.

The present invention discloses one kind of retinol conjugated protein and its preparation process and specific antibody. The present invention expresses retinol conjugated protein effectively for the first time, and the expressed retinol conjugated protein has property near to that of natural retinol conjugated protein (RBP4). Immunizing animal with the expressed retinol conjugated protein can obtain antibody capable of recognizing natural retinol conjugated protein in human body sensitively. The present invention fills in a gap in RBP4 antiserum.

The present invention relates to a method for diagnosing a subject's Alzheimer's disease state. The method involves providing a database containing information relating to protein expression levels associated and not associated with Alzheimer's disease. The database includes information relating to at least a majority of the following proteins: albumin, alpha-1-antitrypsin, apolipoprotin E, apolipoprotein J, complement component 3, contactin, fibrin beta, Ig heavy chain, Ig light chain, neuronal pentraxin receptor, plasminogen, proSAAS, retinol-binding protein, transthyretin, and vitamin D binding protein. Information relating to proteins found in one or more cerebrospinal fluid samples from a subject is also provided and a database is used to analyze the information from the subject to diagnose the subject's Alzheimer's disease state. Also disclosed is a computer readable medium and a system, both useful in carrying out the present invention.

The invention provides a test kit for measuring the content of retinol conjugated protein in serum of a human body and a preparation method of the test kit. The volume ratio of a reagent R1 and a reagent R2 is 3:1. The R1 comprises 0.01-4%w / w of emulsifiers, 0.1-2%w / w of sodium chloride, 0.05-2%w / w of sensitizers, 0.02%w / w of preservative and 30-100mmol / L of buffer solutions. The R2 comprises 0.1-0.5%w / w of latex particle combined with a retinol conjugated protein antibody, 0.1-1.0%w / w of bovine serum albumin, 0.02-2%w / w of Tween 20, 0.02-2%w / w of stabilizers 2, 0.02-2%w / w of protein protective agents, 0.02%w / w of preservative and 20-50mmol / L of buffer solutions. The test kit has wide linearity range, high sensitivity and stability and good clinical application prospect.

The invention relates to a detection kit for a retinol binding protein. The interior of a detection kit body comprises reagents R1 and reagents R2, wherein the reagents R1 comprise a buffer solution, polyethylene glycol, sodium azide, sodium ethylene diamine tetracetate and bovine serum albumin; and the reagents R2 comprise a buffer solution, latex grains combined with retinol binding protein monoclonal antibodies, tween-20, sodium azide, sodium ethylene diamine tetracetate and bovine serum albumin. A sample and the reagents are mixed at a certain volume ratio and generate a series of reactions, and then a reactant is placed under a semi / full-automatic biochemical analyzer, and the speed of absorbance change in the position of a main wavelength of 340nm is detected, so that the concentration magnitude of the retinol binding protein is measured and calculated. The detection kit has the advantages of accuracy, stability and convenience.

New markers for diseased liver conditions have been identified. A combination of protein C (PROC) and retinol binding protein 4 (RBP4) in blood are biomarkers to distinguish patients at different stages of hepatic fibrosis due, for example, to chronic infection with hepatitis C virus (HCV). Also, alpha-1-B glycoprotein (A1BG), complement factor H (CFH) and insulin-like growth factor binding protein acid labile subunit (IGFALS) distinguish subjects with chronic or acute liver conditions such as hepatitis infection or liver fibrosis from healthy controls.

Methods for screening molecules that modulate the activity of Retinol Binding Protein 4 (RBP4) and their use in treatment of insulin resistance are described. Also described are methods of diagnosing insulin resistance and related conditions by detecting modulation of RBP4 activity.

The invention discloses a novel electrochemiluminescence immunosensor for rapid and high sensitive detection of retinol binding protein. By adopting a double-antibody sandwich method, and by making use of the large specific surface area and good electrical conductivity of a multiwalled carbon nanotube and good biocompatibility of SiO2, a regular surface porous structure, high adsorption capacity and other advantages, the dual signal amplified electrochemiluminescence immunosensor can be constructed on a glassy carbon electrode surface and can perform electrochemiluminescence detection on RBP (retinol binding protein) in the human body fluid. Results show that, by employing an electrochemiluminescence immunosensing method, the RBP detection concentration range is wide, the detection limit is low, and the immunosensor has good stability, reproducibility and other sensing properties.

The invention discloses a retinol conjugated protein detection kit. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 is a buffer solution, the reagent R2 is the mixture of retinol conjugated protein antibody sensitized polystyrene latex particles and the buffer solution. The retinol conjugated protein detection kit has the advantages that the kit is simple and quick to detect, high in sensitivity, good in accuracy, good in anti-interference capacity and low in production cost; a lipoprotein a (retinol conjugated protein) detection method adopted by the kit is a latex enhanced immuno-turbidimetry and enables the lipoprotein a (retinol conjugated protein) detection to be more economical, convenient and quicker, and the retinol conjugated protein detection kit is applicable to automatic biochemical analyzers of most of hospitals and especially can achieve quick quantitative detection for emergency treatment.

The invention discloses a kit for determining retinol binding protein (RBP) content through a magnetic particle chemiluminiscence method. The kit comprises a calibrator, a quality controller, resistance reagents, a magnetic particle reagent and a light-emitting substrate; the resistance reagents are a retinol binding protein coated antibody labeled with fluorescein isothiocyanate and a retinol binding protein labeled antibody labeled with alkaline phosphatase; the magnetic particle reagent is a magnetic particle and goat antibody FITC connector. The chemiluminiscence technology and immune magnetic particles are combined, and an approximately homogeneous reaction system is provided; by the adoption of a one-step reaction pattern, detection sensitivity and precision are greatly improved, the detection range is expanded, reaction time is greatly shortened, less than 25 min is spent from sample addition to result detection, and the kit is obviously faster than a similar kit; multiple samples can be tested on fully-automatic chemiluminescence apparatus at the same time, high-flux rapid determination of retinol binding protein is realized, accuracy is high, specificity is high, and precision and detection efficiency are greatly improved.

The invention discloses a retinol binding protein determination kit and a preparation method thereof. The kit comprises a reagent R1 and a reagent R2 which are liquid components and are mutually independent, the reagent R1 comprises a buffer solution, a chelating agent, an accelerator, a stabilizer and an antiseptic, and the reagent R2 comprises the buffer solution, a stabilizer, a surfactant, a suspending aid, the antiseptic and a latex coated anti-retinol binding protein antibody. The preparation method comprises the following steps: preparing the reagents according to the component content; mixing a sample to be determined with the reagent R1 and the reagent R2 to fully react the sample to be determined with the reagent R1 and the reagent R2; determining the absorbance difference by using a fully-automatic biochemical analyzer after the reaction; and calculating the concentration of the retinol binding protein in the sample according to the absorbance change value. The kit has high accuracy.

The invention provides a colloidal gold immunocolorimetry kit for detecting retinol conjugated protein (RBP) and a preparation method of the kit and belongs to the field of in-vitro diagnostic reagents. The kit is used for judging whether the situation of individual acute kidney injury occurs or not. According to the method, colloidal gold particles are adopted as a carrier, a retinol conjugated protein (RBP for short) antibody and the colloidal gold particles are coupled, RBP protein in a sample makes contact with the coupled gold particles in a corresponding detection device, an antigen-antibody-gold compound is formed, the light absorbance of the gold particles under detection wavelength is changed, the change amount of the light absorbance is positively correlated with the concentration of RBP protein, and then the purpose of detecting RBP protein in the sample is achieved. The kit has high analysis sensitivity.

The invention provides a method for producing anti-human retinol conjugated protein antiserum for sheep. The method comprises the following steps of: (1) preparing an antigen; (2) performing injection for the first time; (3) performing injection for the second time; (4) performing injection for the third time; (5) performing injection for the fourth time; (6) performing injection for the fifth time; (7) performing injection for the sixth time; (8) performing injection for the seventh time; (9) performing injection for the eighth time; and (10) detecting serum titer: drawing blood from the vein of the sheep after 8-10 days from the injection each time, separating the serum and detecting dual-extending titer. Compared with the prior art, the method for producing the anti-human retinol conjugated protein antiserum for the sheep, disclosed by the invention, is low in cost, and simple in process; the method not only can stably produce the antibodies, but also is high in antibody producing speed; the antibody level is high, and the dosage of the antigen is small.

The invention provides colloidal gold quick detection test paper of retinal binding protein (RBP) and an application thereof. The detection test paper comprises a test strip and a baseplate for supporting the test strip, wherein the test strip at least comprises a combining and releasing cushion and a detection cushion; retinal binding protein resistant monoclonal antibodies marked by colloidal gold are wrapped on the combining and releasing cushion in advance; and test lines of retinal binding protein resistant polyclonal antibodies are wrapped on the detection cushion in advance. The RBP detection test paper has low cost and easy preservation, has rapidness, convenience, high sensitivity and good accuracy when used for testing the retinal binding protein, is suitable for clinical and household use and has industrialization.

The present invention relates to a tumor marker for diagnosis of ovarian cancer, which is selected from the group consisting of galectin-1, cathepsin B, MHC class I antigen, heat shock protein (HSP) 27, ubiquitin carboxy-termal esterase L1, plasma retinol-binding protein (PRBP), transthyretin, SH3 binding glutamate-rich protein, tubulin-specific chaperone A, RNA binding protein regulatory subunit, γ-actin, tropomyosin and calcium / calmodulin-stimulated cyclic nucleotide phosphatase. The ovarian cancer is diagnosed effectively and efficiently based on detecting the expression levels of the tumor markers in the invention from the ovarian tissue sample of an individual to be diagnosed.

Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and / or prevention of age-related macular degeneration and / or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.

The present invention provides a method of diagnosing the existence of a kidney disorder in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of lumican; collagen alpha 1 (111) chain, variant 12; decorin; secreted frizzled-related protein 2; retinol binding protein 5; MMP-2; MMP-7; and MMP-19, in a biological sample from the feline, wherein differences in expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal animal indicate the existence of a kidney disorder; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.

The invention relates to a hybridoma cell capable of secreting an anti retinol binding protein monoclonal antibody, wherein the hybridoma cell has the preservation number of CCTCC No:C2013132. The hybridoma cell has high secreting yield, and the anti retinol binding protein monoclonal antibody obtained by secretion has the advantages of high affinity and high specificity, can be widely applied in the field of retinol binding protein detection, such as the detection reagent or detection equipment preparation fields and the like, and has significant advantages in specificity, sensitivity, detection rate and other aspects compared with a conventional detection method. In addition, the invention also relates to the monoclonal antibody secreted by the hybridoma cell, the hybridoma cell and an application of the monoclonal antibody.

The invention discloses a performance-stable retinal binding protein quality control product, comprising a matrix fluid and a retinol binding protein. The quality control product also comprises a protein protectant and a preservative, wherein the protein protectant is aminopyrine, polyethylene glycol, gelatin or K30, the preservative is one of NaN3, Bronidox, BIT, MIT, BRO or a mixture of two or more substances. The invention has the advantages of stable performance, strong adaptability, and can be applied to mainstream instruments produced by various manufacturers. The quality control productadopts normal human serum or plasma as a matrix liquid, which is consistent with the clinical sample, thereby minimizing the matrix effect and improving the good stability. The added protectant improves the stability of the quality control product, and the addition of the preservative is effective to prevent the turbidity of the quality control product during use.

The invention discloses a process for purifying a human retinol binding protein and a preparation process of a polyclonal antibody thereof. According to the invention, by using a separation technology by multiple chromatographic columns such as a DEAE-Sepharose Fast Flow (DEAE-S) ion exchange column, a molecular sieve (Superdex 75, Sephacryls-200) and a hydrophobic column Phenyl SepharoseTM High Performance (PHSP), the human retinol binding protein is successfully purified from urine of a patient suffering from renal injury, and the immunogenicity of the RBP protein is remained to the greatest degree. The obtained human RBP antigen is used for immunizing animals, thus obtaining a polyclonal antibody of the human retinol binding protein. The obtained polyclonal antibody of the human retinol binding protein can be applied to an immunonephelometry kit.

The invention relates to a latex enhanced immunoturbidimetric detection kit for retinol binding protein and an application thereof in clinical detection of content of retinol binding protein (RBP4) inserum, and belongs to the field of in vitro diagnosis of medical immunology. The RBP latex enhanced immunoturbidimetric detection kit provided by the invention adopts recombinant expressed rhRBP4 asa calibration product, a quality control product and related rabbit polyantibody immune antigens, and the rabbit polyantibody, the rhRBP4 calibration product and the quality control product are used for preparing the latex enhanced immunoturbidimetric detection kit, and the content of RBP4 in blood can be accurately detected. Compared with commercial products, the kit has better specificity and higher accuracy, and shows better clinical application prospect. Besides, the recombinant expression method of the rhRBP has the characteristics of short period, large expression amount and low cost, and improves the quality uniformity of related products to a great extent.